SLC5A2 and Venous thrombosis: Thus, this study aimed to: (a) evaluate the association between SGLT2 inhibitors and incident heart failure, as well as other non‐heart‐failure‐related adverse cardiovascular events such as mortality, arrhythmias and vascular thrombosis, using a large global federated database and (b) determine whether these results from a real‐world population were consistent with those of RCTs such as EMPA‐REG OUTCOME and DECLARE‐TIMI 58, which were conducted in selective study populations under stringent conditions.